Top Breaking News | More News | Featured Stories | News By Subject | Event News | Investor News | News Archive | Search News
Get Our FREE
Industry eNewsletter
email:    

Investor News

Clinical Development News
Pre-Clinical
IND
Phase I - Safety
Phase II - Safety and Efficacy
Phase III - Controlled Safety and Efficacy
BLA/NDA/ANDA
PDUFA
Approvable Letters
Approval and Marketing Clearance
Post-Approval
Discontinued
Recalls and Warnings

Deals & Dollars News
Alliances
Earnings Reports
Financial
Investor
Mergers and Acquisitions
Start-Ups

IPO News
IPO


Clinical - Phase I
Rock Creek Pharmaceuticals Receives Clinical Trial Application Approval 1/30/2015 7:44:50 AM
First Trial Finds GlaxoSmithKline (GSK) Ebola Shot Safe 1/29/2015 6:49:36 AM
First Trial Finds GlaxoSmithKline (GSK) Ebola Shot Safe 1/29/2015 6:49:36 AM
Endexx Announces Positive Results Of Initial Diabetic Neuropathy Patient Study 1/29/2015 11:34:29 AM
International Stem Cell Corporation To Conduct Parkinson's Disease Clinical Study In Australia 1/29/2015 11:05:23 AM
Cleveland Biolabs Inc. (CBLI) Announces Oncology Clinical Development Update For Entolimod 1/29/2015 10:47:47 AM
Celldex Therapeutics, Inc. (CLDX) And Bristol-Myers Squibb Company (BMY) Announce Initiation Of Phase 1/2 Combination Study Of Varlilumab And Opdivo® In Advanced Refractory Solid Tumors 1/29/2015 7:36:47 AM
Xencor Reports Top-line XmAb®5871 Phase 1b/2a Results Showing Promising Clinical Activity In Rheumatoid Arthritis 1/29/2015 7:28:44 AM
XencorReports XmAb®7195 Top-line Interim Phase 1a Results Showing Rapid Reduction Of Serum Ige In Healthy Volunteers 1/29/2015 7:26:03 AM
Sorrento Therapeutics, Inc. Announces Completion Of Enrollment In The Cynviloq™ Registrational TRIBECA™ Study 1/28/2015 8:25:42 AM
RestorGenex Granted Orphan Drug Designation For RES-529 For Treatment Of Glioblastoma Multiforme 1/28/2015 7:56:46 AM
aTyr Pharma Inc. Announces First FSHD Patient Study Of Resolaris™ 1/28/2015 7:20:52 AM
Opsona Therapeutics Ltd. Initiates A Prospective Open Label Phase 1/2 Study In Second-Line Lower (Low And Intermediate-1) Risk Myelodysplastic Syndrome (MDS) With OPN-305, A First-In Class Monoclonal Antibody That Blocks Toll-Like Receptor 2 1/26/2015 1:27:04 PM
Cellceutix (CTIX) Plans Clinical Trial In Patients With Ulcerative Proctitis 1/26/2015 11:00:33 AM
Pharmacyte Biotech's Expanded Follow-Up Study On Malignant Ascites Fluid Accumulation In Final Stages Of Preparation 1/26/2015 7:50:36 AM
1234567
//-->